Showing results (291-300 of 340) with videos related to
Sort By:
Pageof 34
Diabetes, Obesity & Metabolism|February 7, 2018
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathyHiddo J L Heerspink, Dennis L Andress, George Bakris, et al.Diabetes, Obesity & Metabolism|April 1, 2018
Baseline characteristics and enrichment results from the SONAR trialHiddo J L Heerspink, Dennis L Andress, George Bakris, et al.Clinical Journal of the American Society of Nephrology : CJASN|December 2, 2021
The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Randomized TrialSimke W Waijer, Ron T Gansevoort, George L Bakris, et al.Clinical Journal of the American Society of Nephrology : CJASN|December 8, 2021
Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney DiseaseSimke W Waijer, Taha Sen, Clare Arnott, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 24, 2021
Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE TrialHiddo J L Heerspink, Megumi Oshima, Hong Zhang, et al.Journal of Hypertension|March 14, 2007
Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studiesWouter B A Eijkelkamp, Zhongxin Zhang, Barry M Brenner, et al.American Heart Journal|October 11, 2011
Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)John J V McMurray, Hajime Uno, Petr Jarolim, et al.Journal of the American Heart Association|September 23, 2020
NT-proBNP by Itself Predicts Death and Cardiovascular Events in High-Risk Patients With Type 2 Diabetes MellitusMarcus V B Malachias, Pardeep S Jhund, Brian L Claggett, et al.Diabetes, Obesity & Metabolism|December 27, 2016
The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathyMichelle J Pena, Dick de Zeeuw, Dennis Andress, et al.Drugs in R&D|August 24, 2017
Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled TrialDavid J Webb, Blai Coll, Hiddo J L Heerspink, et al.Pageof 34